NEW YORK (GenomeWeb News) – Direct-to-consumer genetics testing firm 23andMe today said that it has raised more than $50 million in a Series D financing round.

The funds will be used to expand the Mountain View, Calif.-based company's business with the goal of creating an "exponentially larger" group of genotyped individuals and using data from those individuals to conduct research. 23andMe currently has more than 180,000 customers and it aims to eventually reach one million, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.